Filing Flows

Filing Flows › Xenon Pharmaceuticals (XENE) › Who owns the stock

Who owns Xenon Pharmaceuticals (XENE) stock

303 funds reported Xenon Pharmaceuticals (XENE) shares in their latest 13F filings, worth $6.1B in all. The largest holder is FMR LLC ($582M). Last quarter 161 funds added to their stakes and 101 cut them.

Largest holders of XENE (13F)Largest holders of XENE (13F)FMR LLC$582MBlackRock$454MAvoro Capital Advisors LLC$349MPolar Capital Holdings$276MDriehaus Capital Management LLC$267MJupiter Topco LLC$253MJanus Henderson Group$243MPrice T Rowe Associates$196MCapital International Investors$143MT. Rowe Price Investment Manageme…$131M

Largest holders (13F)

FundSharesValueChangeQuarter
FMR LLC9,647,998$582Mdecrease2026-06-30
BlackRock7,522,482$454Mincrease2026-06-30
Avoro Capital Advisors LLC5,777,777$349Munchanged2026-06-30
Polar Capital Holdings4,570,556$276Mincrease2026-06-30
Driehaus Capital Management LLC4,418,557$267Mdecrease2026-06-30
Jupiter Topco LLC4,186,519$253Mbase2026-06-30
Janus Henderson Group4,175,982$243Mincrease2026-03-31
Price T Rowe Associates3,248,219$196Mincrease2026-06-30
Capital International Investors2,361,639$143Mdecrease2026-06-30
T. Rowe Price Investment Management2,168,581$131Mincrease2026-06-30
State Street1,969,629$119Mincrease2026-06-30
Two Sigma Investments, LP1,642,848$99.2Mincrease2026-06-30
Deerfield Management Company, L.P. (series C)1,615,696$97.5Munchanged2026-06-30
Affinity Asset Advisors, LLC1,595,000$96.3Mdecrease2026-06-30
Westfield Capital Management Co LP1,507,294$91.0Mincrease2026-06-30

Xenon Pharmaceuticals' latest quarter

Xenon Pharmaceuticals, Q1 2025: revenue $7.5M, operating margin -969.8%, net loss $65.0M, operating cash flow −$61.7M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most XENE stock?

By the latest 13F filings: FMR LLC ($582M); BlackRock ($454M); Avoro Capital Advisors LLC ($349M); Polar Capital Holdings ($276M); Driehaus Capital Management LLC ($267M).

What is the short interest in XENE?

7,348,577 shares were sold short at the 2026-10-15 settlement, 21.64% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.